Scholar Rock Holding (FRA:2QK) Short Percentage of Float


FRA:2QK Scholar Rock Holding Corp FRA:2QK
26 GF Score
Price €48.00
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:2QK vs COGT, CGON, PTCT: Short Percentage of Float Comparison

For the Biotechnology subindustry, Scholar Rock Holding's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scholar Rock Holding Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Scholar Rock Holding's Short Percentage of Float falls into.


FRA:2QK
26GF Score
Scholar Rock Holding Corp FRA:2QK
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
26GF Score

Get the complete analysis for FRA:2QK

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.00
Price